U.S., March 11 -- ClinicalTrials.gov registry received information related to the study (NCT06867965) titled 'Feasibility Study of a Novel Subcutaneous Continuous Glucose Monitoring System in Diabetics' on March 04.
Brief Summary: Mono-centre, open label (unblinded). 8 patients + 2 potential replacements. Duration up to 9 weeks: up to 6 weeks screening (42 days), 2 weeks of treatment (14 days, depending on sensor functionality) and 1 week of follow up (7 days)
Study Start Date: March, 2010
Study Type: INTERVENTIONAL
Condition:
Diabetes
Intervention:
DEVICE: BellySense
BellySense is a novel CGM system, based on a fiber-optical sensor placed through the dermis of the patient.
Recruitment Status: COMPLETED
Sponsor: EyeSense GmbH
Pub...